Lect 1-Compounding and Dispensing

8/18/2019 Lect 1-Compounding and Dispensing

1/21

COMPOUNDING ANDDISPENSING

OLEH :

ANI PAHRIYANI, M.SC., APT

PROGRAM STUDI PROFESI APOTEKERFAKULTAS FARMASI DAN SAINS

UNIVERSITAS MUHAMMADIYAH PROF. DR.HAMKA

JAKARTA2015


2/21

STANDAR PELAYANAN KEFARMASIAN DIAPOTEK Pere!"e# RI N$. %5 &'()! 201*

•S&'!+'r e-''!'! "e/'r'#'! + '$&e" e-)& :

'. e!e-$-''! Se+''! F'r'#, A-'& Ke#e('&'!, +'! '('! Me+# H'3# P'

3. e-''!'! /'r'# "-!".

Pe-''!'! F'r'# K-!" e-)&

4. e!"''! Re#e6

+. +#e!#!6

e. Pe-''!'! I!/$r'# O3'& 7PIO86

/. "$!#e-!6

. Pe-''!'! Ke/'r'#'! + r)'( 7($e ('r'4 4're86

(. Pe'!&')'! Ter' O3'& 7PTO86 +'!

. M$!&$r! E/e" S'! O3'& 7MESO86


3/21

KOMPONEN PRAKTIKUM COMPOUNDINGAND DISPENSING 7RESEP KERING8

Re#e ('r)# +!-' 3er+'#'r"'! "e&e!&)'!9"e&e!&)'! +'-' :

A. Skrining Resep

. Skrining Administratif

. Skrining Farmasetis

. Skrining Farmakologi

. Pe!''! Obat

. Peracikan

. Etiket. Pengemasan.

C. Penyerahan Obat

D. Monitoring Penggnaan Obat

E. !ain"lain

. Cara membat salinan resep

. Pengisian PMR.


4/21

SKRINING FARMAKOLOGI

1. A-er;ESO '! )&'';ADR &er"'& $3'&

2. I!&er'"# /'r'"$"!e&";/'r'"$+!'"


5/21

ALERGI ; ESO ; ADR

A-er :

US NLM : A! '--er # ' re'4&$! 3 $)r )!e ##&e &$ #$e&(! &('& +$e# !$&

e$-e. Pe$-e ?($ ('>e '--ere# $/&e! 're #e!#&>e &$ $re &('! $!e &(!.

A--ere# 4'! 4')#e ' >'re& $/ #&$# #)4( '# ' r)!! !$#e, #!ee@!, &4(!

$r '#&('. A--ere# 4'! r'!e /r$ !$r &$ #e>ere. A!'(-'# # ' #e>ere re'4&$!

&(re'&e!!

ESO 7E/e" S'! O3'&8

A #+e eBe4& # )#)'-- re'r+e+ '# '! )!+e#r'3-e #e4$!+'r eBe4& ?(4( $44)r# ! '++&(er'e)&4 eBe4& $/ ' +r) $r e+4'&$!. S+e eBe4 ' >'r /$r e'4( !+>+)'-

er#$!# +#e'#e #&'&e, 'e, ?e(&, e!+er, e&(!4& '!+ e!er'- (e'-&(. (e! #+e eBe+4'&$! 're #e>ere, &(e +$#'e ' 3e '+)#&e+ $r ' #e4$!+ e+4'&$! '

7???.+r)#.4$8

ADR 7A+>er#e Dr) Re'4&$!#8

A+>er#e +r) re'4&$! '# '! 're4'3- ('r/)- $r )!-e'#'!& re'4&$!, re#)-&! /r$re-'&e+ &$ &(e )#e $/ ' e+4!'- r$+)4&. A+>er#e +r) re'4&$!# 're 4-'##=e+ !&

!e$!4#8: +$#e9re-'&e+ 7A)e!&e+8, !$!9+$#e9re-'&e+ 7@'rre8, +$#e9re-'&e+ '!+ &e

&e9re-'&e+ 7De-'e+8, ?&(+r'?'- 7E!+ $/ )#e8, '!+ /'-)re $/ &(er' 7F'-)re8. 7L'!4e&, 20


6/21

INTERAKSI OAT

I!&er'"# $3'& '+'-'( er#&?' +'!' '"# #)'&) $3'& + )3'( '&') +e!'-'! '! + 3er"'! 3er#'''!.

e!&)"93e!&)" !&er'"# 3er+'#'r"'! e"'!#e "er'!'

'. I!&er'"# /'r'#e&"

3. I!&er'"# /'r'"$"!e&"

4. I!&er'"# /'r'"$+!'"

er+'#'r"'! @'& '! 3er!&er'"#, +3e+'"'! e!'+

+. I!&er'"# $3'&9 $3'&

e. I!&er'"# $3'& '"'!'!

/. I!&er'"# $3'& 9 e!'"&


7/21

INTERAKSI FARMAKOKINETIK

I!&er'"# /'r'"$"!e&" &er'+ 3-' #'-'( #'&) $3'& ee!'r)( '3#$e&'3$-#e '&') e"#"re# $3'& "e+)' #e(!' "'+'r -'#' $3'& "e+)' e!)r)!.

'. I!&er'"# r$#e# '3#$r# I!&er'"# ! +''& &er'+ '"3'& er)3'('! (er&''. Pe!'r)( '3#$r# #)'&) $3'& )!"! &er'+ '"3'& e!)r'!+'-' #'-)r'! 4er!' '&') '"3'& e3e!&)"'! "$-e"#.

3. I!&er'"# r$#e# +#&r3)# J"' +'-' +'r'( '+' #''& '! #'' &er+''&'+' r$&e! -'#'. K$e&# )!&)" "'&'! +'-' 'r!'! &er'+ +$! +'! ")!+! +e!'! '"3'& e!!"'&'! "'+'r -'#' +$!.

4. I!&er'"# '+' r$#e# e&'3$-#e I!&er'"# +'-' e&'3$-#e +''& &er'"e)!"!'!, '"! e'4) e!@ '&') e!('3'& e!@. S)'&) $3'& e'4) e&'3$-#e $3'& -'! 7$3'& $3e"8 #e(!' eer4e'& e-!'

+. I!&er'"# '+' r$#e# e-!'# I!&er'"# '+' r$#e# e-!'# e-') !

'"3'& er)3'('3 PH +'-' )r! '&') "'re!' er#'!'! &e'& "'&'&r'!/$r'# '! 3er/)! # )!&)" e"#"re#


8/21

INTERAKSI FARMAKODINAMIK

I!&er'"# /'r'"$+!'" '+'-'( !&er'"# '!&'r' $3'&9$3'& '! e)!'e/e" #'! '! 3er-'?'!'!. I!&er'"# ! +#e3'3"'! $-e( "$e&# '+'#'', '&') &er'+'!&'r' $3'&9$3'& '! 3e"er' '+' ##&e =#$-$" '!

E/e" '! &er'+ '+' !&er'"# /'r'"$+!'", +'!&'r'!':

'. S!er#e I!&er'"# /'r'"$+!'" '! '-! )) &er'+ '+'-'( #!er

+)' $3'& '! 3e"er' '+' ##&e, $r'!, #e- '&') e!@ '! #'' +e!'/'r'"$-$ '! #''

3. A!&'$!#e I!&er'"# &er'+ 3-' $3'& '! 3er!&er'"# e-" e/e" /'r3er-'?'!'! #e(!' e!'"3'&"'! e!)r'!'! ('#- '! +!!"'! +'-e3( $3'&.

4. E/e" re#e&$r &+'" -'!#)! K$3!'# ! +''& 3e"er' e-'-) e"'!#ee!'r)( e/e" re#e&$r '! e-)& #r")-'# "e!+'- =#$-$ '&') 3


9/21

CONTOH INTERAKSI OAT 9 OAT

Cipro#oksasin $s %alsim

"'-#) e!)r)!"'! '3# 4r$

Pe!'&'#'!: Cr$ +!) +)-) 2 ' #e3e-) K'-#)

Aspirin $s cipro

A#r! e!)r)!"'! e/e" 4r$

Cipro $s amiodarone

K$3!'# "e+)'!' eer3)r)" "e'+''! 'r&' 7e!!"'&'! !&er>'- T8

Amiodarone $s sim$astatin

K$3!'# "e+)'!' e!!"'&"'! "e'+'! $'&(


10/21

CONTOH INTERAKSI OAT 9 PENYAKIT

A#r! '+' &)"'" -'3)! (!+'r

C'-#) &+'" +re"$e!+'#"'! '+' e!+er&' ''- !$+er'&e

Cr$ e!!+)"# &er'+!' re!'- 're!& e!)+$## '+ 250 , 2 #e('r


11/21

CONTOH INTERAKSI OAT 9 MAKANAN

&etracyclines and milk prodcts

'arfarin and $itamin %"containing foods

(rapefrit )ice

Co*ea +ith anti"hypertension drgs


12/21

LITERATUR

1. K$+'9K3-e MA Y$)! LY 718 H'!#&e! '!+ H$r!# M'C-!4'-- I$r&'!& Dr) I!&er'4&$!#, A-e+ T(er'e)&4V'!4$)>er

2. K$+'9K3-e e& '- 72008 H'!+3$$" $/ A-e+ T(er'e)&4

L!4$&& --'# -"!#, P(-'+e-('%. M$@''! A R'$! LP 7200*8 H'!+3$$" $/ Dr) I!&er'4

C-!4'- '!+ F$re!#4 G)+e, H)'!' Pre##, Ne? Jer#e

*. R$+r)e# AD 720028 Dr)9Dr) I!&er'4&$!#, T'-$r Fr'! Y$r"

5. S&$4"-e IH 71*8 Dr) I!&er'4&$!#, %r+ e+, -'4"?e-- S4e


13/21

ESITE TOOLS

???.'r@$!'4er&.$r 7+r) !&er'4&$!#8

???.+r)9!&er'4&$!#.4$7P*509e+'&e+ +r) !&er'4&$!#8

???.&$r#'+e#.$r 7+r)9!+)4e+ 'rr(&('8

???.e!!4er&.$r 7'!&3$&4#8

???.+4r.+)"e.e+);re#e'r4(;=e-+#;4er.(&- 74'r+$>'#4)&(er'e)&4#8

???.#(.)!4.e+);(e'-&($)&4$e#;4er!+e.(&7&(er'e)&4# ! e+'&r4#8

???.)'3.e+)

7&(er'e)&4# $/ )#4)-$#"e-e&'- +#$r+er#8


14/21


15/21

DO!

• Dosis Sub terapi

Kesalahan penetapan dosis

Frekuensi pemakaian yang tidak tepat

Lama pemakaian yang tidak tepat

Penyimpanan tidak benar

Cara/rute penggunaan yang tidak benar

• Dosis terlalu besar

Kesalahan penetapan dosis

Frekuensi pemakaian tidak tepat

Lama pemakaian tidak tepat


16/21

"djusment dose

"djusment dose #

a. Hepatic disfunction

Liver dysfunction may not only reduce the blood/plasma clearance of drugs elim

metabolism or biliary excretion, it can also affect plasma protein binding, which in turn

processes of distribution and elimination (erbeec!, "##$%.

b. &idney disease.

'hronic !idney disease affects renal drug elimination and other pharmaco!inetic pro

drug disposition (e.g., absorption, drug distribution, nonrenal clearance metabolism)% (&

c. *bese patients

'lassical pharmaco!inetic parameters such as volume of distribution (V d%, clearanc

binding can change for some drugs in morbidly obese patients. Highly lipophilic

barbiturates and ben-odia-epines show significant increases in V d for obese individuals


17/21

$%R&!'*" DO!

a. +erdasarkan +erat +adan

lark-s rule

Dosis "nak +erat +adan (lb) 0 Dosis De1asa

234

berat badan bukan dalam kg, tapi lb dimana 2kg5,5lb


18/21

b. +erdasarkan mur

6oung-s rule (anak 7 8 th)

Dosis "nak mur (tahun) 0 Dosis De1asa mur925

anak : ; 8 thDosis "nak (mur )0 Dosis De1asa

54


19/21

c. +erdasarkan >uas $ermukaan 'ubuh (+od= urface "rea)

Rumus menghitung +"

?osteller +" akar kuadrat dari tinggi badan (cm) 0 berat badan (

@A44

Dosis "nak ?osteller +" 0 Dosis De1asa

2,B@


20/21

?odifikasi skala Denekamp


21/21

'%R!?"K"!&

ASSALAMUALAIKUM R. .

Lect 1-Compounding and Dispensing

Documents

Transcript of Lect 1-Compounding and Dispensing